Submission guidelines
:: GENERAL INFORMATION
• The total cost of the meeting is the same whether or not you submit an abstract.
• A maximum of two abstracts will be accepted per presenting author. The author presenting the study will be required to register for the Congress.
• Submitting an abstract does not constitute or guarantee registration. It is best to register early.
• Accepted abstracts will be included in a CD and distributed only for registered participants.
• NO ABSTRACT WILL BE ACCEPTED AFTER THE DEADLINE MAY 5th, 2012.
• Submissions will be analyzed by peer reviewers appointed by the Organizing Committees. These Committees will verify the adequacy of the abstracts for presentation at the Meeting.
• The Organizing Committee reserves the right to refuse any abstracts judged inadequate.
• All abstracts will be scheduled for poster presentation.
• OUTSTANDING ABSTRACTS WILL BE SELECTED FOR ORAL PRESENTATION.
• “REMINDER: Participants are encouraged to present your work in ENGLISH if your abstract is selected for oral presentation”.
• Only one certificate will be issued per abstract and, stating the title and names of all authors, according to the text submitted by the presenting author, who will receive the certificate at the meeting venue.
• Only one certificate will be issued per oral presentation, stating the title and names of all authors, according to the text submitted by the presenting author, who will receive the certificate at the meeting venue.
:: ABSTRACT FORMAT
• Abstracts should be written in English and submitted by the e-mail: abstract@cemcerimonia.com.br
• The subject of the e-mail should be your name and your registration number.
• Please include all information requested in the fields. The main body of the abstract cannot exceed 3000 characters including space.
• The following subheadings should be included in the main body of the abstract: Introduction, Objectives, Methodology, Results, Conclusions and Financial support (see the model).
• Abstracts not complying with the above specifications will not be accepted.
• Special attention should be given to written English, as abstracts containing spelling, orthographic or grammatical mistakes will be rejected.
• There is no fee for abstract submission. However, abstracts will only be fully processed after registration of the presenting author.
• The acceptance letter for the approved abstract will be available on the website as from April 30, 2012, including all necessary information and rules for poster presentation.
:: MODEL
Prolonged survival of allografts induced by mycobacterial Hsp70 is mediated by CD4+CD25+ regulatory T cells
Thiago J. Borges1, Bárbara N. Porto1, César A. Teixeira1, Marcelle Rodrigues1, Felipe D. Machado1, Ana Paula Ornaghi1, Ana Paula D. de Souza1, Fabio Maito1, Wander R. Pavanelli2, João S. Silva2, Cristina Bonorino1
1Faculdade de Biociências e Instituto de Pesquisas Biomédicas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
2Departamento de Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
Introduction: Heat shock proteins (Hsps) are stress induced proteins with immunomodulatory properties. The Hsp70 of Mycobacterium tuberculosis (TBHsp70) has been shown to have an anti-inflammatory role on rodent autoimmune arthritis models, and the protective effects were demonstrated to be dependent on interleukin-10 (IL-10). We have previously observed that TBHsp70 inhibited maturation of dendritic cells (DCs) and induced IL-10 production by these cells, as well as in synovial fluid cells.
Objectives: We investigated whether TBHsp70 could act as an immunosuppressant in two allograft rejection systems and whether the treatment with this protein would be mediated by regulatory T cells (Tregs).
Methodology: We performed two murine skin allograft systems, a transplanted allogeneic melanoma and a regular skin allograft. Graft acceptance was photographed and recorded daily. Treg recruitment was assessed by immunohistology and its induction in draining lymph nodes was analyzed by flow cytometry. Murine cell culture supernatants were analyzed by ELISA for IL-10 production. For Treg depletion, mice were injected i.p. twice with 150 µg of anti-CD25 mAb, purified from PC61 hybridoma.
Results: Treatment with TBHsp70 significantly inhibited acute rejection of the tumor graft, and correlated with regulatory T cells (Tregs) recruitment. This effect was not tumor mediated because injection of TBHsp70 in tumor-free mice induced an increase of Tregs in the draining lymph nodes as well as inhibition of proliferation of lymph node T cells and an increase in IL-10 production. To further characterize the immunosuppressive effect of TBHsp70 over allograft rejection, and to eliminate the tumor cell variable, we switched to a traditional skin allograft model. Treatment with TBHsp70 significantly delays skin allograft rejection (p= 0.0455). Depletion of CD25+ T cells in TBHsp70 treated mice completely abolished the suppression effect. While TBHsp70-treated skin allografts had a significant prolonged survival compared to PBS treated grafts (p= 0.0295), mice that were treated with PC61 mAb and TBHsp70 showed graft survival similar to the PBS treated controls (p= 0.3018), as well as to the ones treated with PBS and PC61 mAb (p= 0.2122). Taken together, these results indicate that the TBHsp70-induced delay of skin graft rejection is mediated by Treg cells.
Conlusions: TBHsp70 has immunosuppressive properties that are dependent on Treg cells, which constitute a major T cell subpopulation that prevent exacerbation of inflammatory responses. This finding is relevant for the elucidation of the immunomodulatory mechanism of TBHsp70. We propose that this protein can be used not only for chronic inflammatory diseases, but is also useful for organ transplantation management.
Financial support: FINEP and CNPq.
:: POSTER GUIDELINES
SUGGESTIONS FOR PREPARING POSTERS
A poster presentation combines a visual display on a poster board of the highlights of research with a question-and-answer opportunity at a specified time. The schedule of fixing poster will be from 8am to 18pm.
Content:
•The poster should show the full title of your abstract.
•Text should be brief and well organized, presenting only enough data to support your conclusions.
•The text should make clear the significance of your research.
•The text should include (most likely as separate elements of the poster) your hypothesis, methods, results, and conclusions.
Design:
•The poster dimensions can be a maximum of 120cm x 90cm with a vertical format. These dimensions are easier to design and view the poster. Please note the poster size and be attentive not to exceed these dimensions. Posters exceeding these measurements and extending into areas reserved for other posters will be removed.
•A clear, simple, uncluttered arrangement is the most attractive and the easiest to read.
•The title lettering should be approximately 8cm high, with authors' names and affiliations in somewhat smaller print.
•Font type size should be at least 66 point for the title, 54 pt. for the authors and 32 pt. for the body text. The typeface chosen should be a simple and clear one (e.g.,Times New Roman or Arial).
•Color should be used sparingly, to provide contrast. The featured parts of the poster can be highlighted with warm colors, and the less important parts can be done in cool colors. Some suggestions for color combinations are as follows: Green on white, red on white, black on white, blue on white, white on blue, and white on black.
•Illustrations should be simple and eye-catching, with unnecessary detail left out. If possible, convert tables to graphic displays. Pie graphs can be used to show parts of a whole, line graphs can be used to show trends or changing relationships, and bar graphs can be used to show volumes.
•Photos should be enlarged enough to show relevant detail.
•Standard computer printouts do not work well on posters, because the type is too small and the lines are too thin to be seen from a distance.
•Patient confidentiality must be protected. No names (or other identifiers, i.e. social security numbers, medical record number, birthdates, etc.) should appear in illustrations.
